Supplying our medicines

during the Brexit transition

Lilly’s top priority is to ensure patients in the UK and in the EU can access the medicines they rely on.

This has required us to plan for a worst-case “hard Brexit” in March 2019 and we have undertaken comprehensive analysis of the risks this scenario could cause across our business, and critically, to our ability to supply medicines in the UK.

Lilly has worked with Government, the NHS and the broader health system through this planning process, providing expertise and data to support national contingency planning and cooperating with the Department of Health and Social Care’s stockpiling strategy.

Lilly’s investment in planning for Brexit has been significant and in many cases our planning, including our own medicines stockpiling, exceeds government guidance. While we have done everything in our power to prepare for Brexit, circumstances outside of our responsibility may still disrupt medicines supply. This includes delays at ports of entry, freight capacity on sea and air routes, and volatility in demand for medicines due to stockpiling outside of our supply chain.

We believe that UK patients should not be disadvantaged by the UK leaving the EU and our focus will remain firmly on ensuring we can supply Lilly medicines to the patients that need them.

In the event that a pharmacist is having difficulty accessing Lilly medicines, they should contact Lilly in the usual way.